Predictors of treatment switching in the Big Multiple Sclerosis Data Network

- Spelman, Tim, Magyari, Melinda, Hyde, Robert, Duquette, Pierre, Lechner-Scott, Jeannette, Sajedi, Seyed Aidin, Lalive, Patrice, Shaygannejad, Vahid, Ozakbas, Serkan, Eichau, Sara, Alroughani, Raed, Terzi, Murat, Butzkueven, Helmut, Girard, Marc, Kalincik, T, Grand'Maison, F, Skibina, O, Khoury, SJ, Yamout, B, Sa, MJ, Gerlach, O, Blanco, Y, Karabudak, R, Van Der Walt, Anneke, Oreja-Guevara, C, Altintas, A, Hughes, S, Mccombe, P, Ampapa, R, de Gans, K, Mcguigan, C, Soysal, A, Prevost, J, John, N, Vukusic, Sandra, Inshasi, J, Stawiarz, L, Manouchehrinia, A, Forsberg, L, Sellebjerg, F, Glaser, A, Pontieri, L, Joensen, H, Rasmussen, PV, Sejbaek, T, Trojano, Maria, Poulsen, MB, Christensen, JR, Kant, M, Stilund, M, Mathiesen, H, Hillert, J, Iaffaldano, Pietro, Horáková, Dana, Drahota, Jiří, Pellegrini, Fabio

Comparative efficacy of first-line natalizumab vs IFN-ß or glatiramer acetate in relapsing MS

- Spelman, Tim, Kalincik, Tomas, Havrdová, Eva, Horáková, Dana, Grammond, Pierre, Duquette, Pierre, Prat, Alexandre, Iuliano, Gerardo, Terzi, Murat, Izquierdo, Guillermo, Hupperts, Raymond M.M., Jokubaitis, Vilija, Lechner-Scott, Jeannette, Zhang, Annie, Pellegrini, Fabio, Wiendl, Heinz, Belachew, Shibeshih, Hyde, Robert, Verheul, Freek, Lugaresi, Alessandra

Comparative efficacy of switching to natalizumab in active multiple sclerosis

- Spelman, Timothy, Kalincik, Tomas, Grand-Maison, Francois, Izquierdo, Guillermo, Grammond, Pierre, Duquette, Pierre, Lugaresi, Alessandra, Lechner-Scott, Jeannette, Oreja-Guevara, Celia, Hupperts, Raymond, Petersen, Thor, Barnett, Michael, Zhang, Annie, Trojano, Maria, Butzkueven, Helmut, Pellegrini, Fabio, Wiendl, Heinz, Kappos, Ludwig, Tsvetkova, Larisa, Belachew, Shibeshih, Hyde, Robert, Verheul, Freek